Acta Scientific Pharmacology

Opinion Volume 3 Issue 4

Aducanumab, an FDA Approved Drug for Alzheimer’s Disease

Suman Chowdhury*

Department of Pharmacology, Physiology, Neuroscience, Rutgers University, USA

*Corresponding Author: Suman Chowdhury, Department of Pharmacology, Physiology, Neuroscience, Rutgers University, USA.

Received: February 09, 2022 Published: March 30, 2022


Alzheimer’s disease (AD) is an irreversible, progressive and most common cause of dementia that destroys memory and thinking skill, it remains a global health concern with ever aging population. Discovered by Alois Alzheimer’s in 1906 [1], AD have been identified in 43.8 million people worlds wide [2]. The pathological hallmarks of AD are intraneuronal neurofibrillary tangles (NFTs), extracellular deposits of amyloid-β (Aβ) peptides as ‘‘senile’’ β-amyloid plaques and decrease in neuronal cells.


  1. Hippius Hanns and Gabriele Neundörfer. "The discovery of Alzheimer's disease”. Dialogues in Clinical Neuroscience1 (2003): 101.
  2. Nichols Emma., et al. "Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016”. The Lancet Neurology1 (2019): 88-106.
  3. Cummings Jeffrey L., et al. "The costs of developing treatments for Alzheimer's disease: A retrospective exploration”. Alzheimer's and Dementia(2021).
  4. Alzheimer's Association. "Changing the trajectory of Alzheimer's disease”. Facts and Figures(2010).
  5. US Food and Drug Administration. "FDA grants accelerated approval for Alzheimer’s drug” (2021): 2021.
  6. Sevigny Jeff., et al. "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease”. Nature7618 (2016): 50-56.
  7. Weitz Tara M and Terrence Town. "Amyloid cascade into clarity”. Immunity4 (2016): 717-718.
  8. Siemers Eric R., et al. "Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients”. Alzheimer's and Dementia2 (2016): 110-120.
  9. Salloway Stephen., et al. "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease”. New England Journal of Medicine4 (2014): 322-333.
  10. Honig Lawrence S., et al. "Trial of solanezumab for mild dementia due to Alzheimer’s disease”. New England Journal of Medicine4 (2018): 321-330.
  11. Cummings Jeffrey L., et al. "ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease”. Neurology21 (2018): e1889-e1897.
  12. Mahase Elisabeth. "Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns”. BMJ 375 (2021): n3127.


Citation: Suman Chowdhury. “Aducanumab, an FDA Approved Drug for Alzheimer’s Disease". Acta Scientific Pharmacology 3.4 (2022): 26-28.


Copyright: © 2022 Suman Chowdhury. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US